Zentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Zentalis Pharmaceuticals (NASDAQ:ZNTL) released its quarterly earnings data on Tuesday. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.01), FiscalAI reports.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL stock opened at $4.28 on Thursday. The firm has a market capitalization of $304.69 million, a PE ratio of -2.47 and a beta of 1.99. The firm has a fifty day simple moving average of $3.43 and a two-hundred day simple moving average of $2.47. Zentalis Pharmaceuticals has a 12 month low of $1.13 and a 12 month high of $6.95.

Institutional Trading of Zentalis Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Voleon Capital Management LP bought a new stake in Zentalis Pharmaceuticals during the 3rd quarter valued at $41,000. Qube Research & Technologies Ltd bought a new stake in Zentalis Pharmaceuticals during the 2nd quarter valued at $37,000. Algert Global LLC bought a new stake in Zentalis Pharmaceuticals during the 3rd quarter valued at $73,000. Corient Private Wealth LLC bought a new stake in Zentalis Pharmaceuticals during the 2nd quarter valued at $83,000. Finally, Opal Capital LLC bought a new stake in Zentalis Pharmaceuticals during the 4th quarter valued at $98,000.

Analyst Upgrades and Downgrades

ZNTL has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Tuesday, April 7th. Guggenheim lifted their price objective on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, April 10th. Wall Street Zen lowered shares of Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Finally, Wells Fargo & Company initiated coverage on shares of Zentalis Pharmaceuticals in a research note on Tuesday, March 17th. They issued an “equal weight” rating and a $5.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Zentalis Pharmaceuticals has an average rating of “Hold” and a consensus target price of $5.83.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.